SCHEMBL4931044

SCHEMBL4931044

CC#C[C@H](C)OS(C)(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
USP2 O75604 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496608 1.00 ALDH1A1 (0.48) ALDH1A1USP2TSHR
SCHEMBL577526 1.00 ALDH1A1 (0.48) ALDH1A1USP2TSHR
SCHEMBL2106256 0.87 ALDH1A1 (0.55) ALDH1A1USP2TSHR
SCHEMBL2102655 0.82 ALDH1A1 (0.32) ALDH1A1
SCHEMBL5552504 0.78
SCHEMBL7596976 0.77 ALDH1A1 (0.43) ALDH1A1USP2TSHR
SCHEMBL16648954 0.76
Lithium Ion SCHEMBL28322039 0.76
SCHEMBL2381500 0.75 ALDH1A1 (0.42) ALDH1A1
SCHEMBL7663302 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237832-A1 SYNTHESIS OF HDAC INHIBITORS: TRICHOSTATIN A AND ANALOGUES UNIVERSITY OF NOTRE DAME DU LAC (US) 2011-09-29 US disclosed
US-20080194841-A1 Preparation of Optically Pure Beta-Amino Acids Having Affinity for the Alpha-Delta Protein PFIZER INC. 2008-08-14 US disclosed
EP-1863780-A1 PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN Pharmacia & Upjohn Company LLC (US) 2007-12-12 EP disclosed
WO-2006100568-A1 PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
US-20050009845-A1 Thienopyrimidine compounds as protein tyrosine kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2005-01-13 US disclosed
EP-1463507-A1 THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS SmithKline Beecham Corporation (US) 2004-10-06 EP disclosed
WO-2003053446-A1 THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009845-A1 Thienopyrimidine compounds as protein tyrosine kinase inhibitors ERBB2, ERBB4, ERBB3 ALDH1A1 1548/4885USP2 3818/4885TSHR 943/4885
US-20110237832-A1 SYNTHESIS OF HDAC INHIBITORS: TRICHOSTATIN A AND ANALOGUES HDAC1, HDAC8, HDAC4 ALDH1A1 1277/4885USP2 2813/4885TSHR 908/4885
US-20080194841-A1 Preparation of Optically Pure Beta-Amino Acids Having Affinity for the Alpha-Delta Protein OPRD1, CHRND, CHRNE ALDH1A1 2244/4885USP2 3091/4885TSHR 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.